ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/000/ERR9822800/ERR9822800_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/000/ERR9822810/ERR9822810_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/001/ERR9822801/ERR9822801_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/008/ERR9822808/ERR9822808_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/004/ERR9822804/ERR9822804_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/000/ERR9822800/ERR9822800_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/009/ERR9822809/ERR9822809_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/001/ERR9822801/ERR9822801_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/001/ERR9822811/ERR9822811_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/007/ERR9822807/ERR9822807_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/002/ERR9822802/ERR9822802_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/003/ERR9822803/ERR9822803_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/008/ERR9822808/ERR9822808_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/004/ERR9822804/ERR9822804_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/003/ERR9822803/ERR9822803_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/005/ERR9822805/ERR9822805_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/000/ERR9822810/ERR9822810_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/006/ERR9822806/ERR9822806_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/002/ERR9822802/ERR9822802_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/009/ERR9822809/ERR9822809_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/005/ERR9822805/ERR9822805_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/001/ERR9822811/ERR9822811_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/006/ERR9822806/ERR9822806_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/ERR982/007/ERR9822807/ERR9822807_1.fastq.gzprimaryOK200GenomicsCenter for medical genetics, Universitair Ziekenhuis Brussel, UZ BrusselEuropean Bioinformatics Institutehttps://www.ebi.ac.uk/ena/browser/view/PRJEB53363ArrayExpressTasquinimod is a new immunomodulatory treatment for MM that is in phase I/II clinical evaluation in patients with relapsed/refractory MM. In the present study, we evaluated the effect of tasquinimod on MM cells using RNA sequencing to provide more mechanistic insights into the observed tasquinimod-mediated anti-tumor effects.ENAP1, M(2)21C1-2, data, 4-hydroxy-5-methoxy-N, RpP2, M(2)21C, RpA2, 2-dihydroquinoline-3-carboxamide., CG4087, LP1, 1-dimethyl-2-oxo-N-((4-trifluoromethyl)phenyl)-1, ABR-215050, Whole Transcriptome Shotgun Sequencing, RLA1_DROME, RNA-seq, rpP2, Rplp1, RPP1, lp-1, rpa2, rpA2, rp21C, DmelCG4087P1, M(2)21C1-2, data, 4-hydroxy-5-methoxy-N, RpP2, M(2)21C, RpA2, 2-dihydroquinoline-3-carboxamide., CG4087, LP1, 1-dimethyl-2-oxo-N-((4-trifluoromethyl)phenyl)-1, ABR-215050, Whole Transcriptome Shotgun Sequencing, RLA1_DROME, RNA-seq, rpP2, Rplp1, RPP1, lp-1, rpa2, rpA2, rp21C, DmelCG4087falseRNA-seq data of LP1 multiple myeloma cell line treated for 6h or 24h with TasquinimodRNA-seq data of LP1 multiple myeloma cell line treated for 6h or 24h with Tasquinimod2023-03-132023-03-13PRJEB53363